[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "phone": "44 203 9206789", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 47, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1041809, "exercisedValue": 0, "unexercisedValue": 6715049}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 55, "title": "Chief Administrative Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 710304, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Dr. Antoine  Yver M.D., M.Sc.", "age": 65, "title": "Executive VP & Chairman of Development", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 773138, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 52, "title": "Principal Accounting Officer & CFO", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 52, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 42, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 55, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harris L. Rotman Ph.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick  Yue M.D.", "title": "Senior VP of Clinical Development & Innovative Medicines", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.32, "open": 11.38, "dayLow": 10.73, "dayHigh": 11.38, "regularMarketPreviousClose": 11.32, "regularMarketOpen": 11.38, "regularMarketDayLow": 10.73, "regularMarketDayHigh": 11.38, "beta": 1.385, "forwardPE": -5.7956986, "volume": 71019, "regularMarketVolume": 71019, "averageVolume": 397148, "averageVolume10days": 127310, "averageDailyVolume10Day": 127310, "bid": 10.67, "ask": 10.85, "bidSize": 300, "askSize": 100, "marketCap": 1081298688, "fiftyTwoWeekLow": 3.96, "fiftyTwoWeekHigh": 12.45, "priceToSalesTrailing12Months": 157.78471, "fiftyDayAverage": 10.5909, "twoHundredDayAverage": 7.8233, "currency": "USD", "enterpriseValue": 909841088, "floatShares": 43888825, "sharesOutstanding": 100306000, "sharesShort": 1738229, "sharesShortPriorMonth": 1536581, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0173, "heldPercentInsiders": 0.02328, "heldPercentInstitutions": 0.84023005, "shortRatio": 8.43, "shortPercentOfFloat": 0.0235, "impliedSharesOutstanding": 100306000, "bookValue": 2.392, "priceToBook": 4.506689, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -151084992, "trailingEps": -1.57, "forwardEps": -1.86, "enterpriseToRevenue": 132.765, "enterpriseToEbitda": -5.322, "52WeekChange": 1.3744493, "SandP52WeekChange": 0.21828604, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.78, "targetHighPrice": 20.0, "targetLowPrice": 8.0, "targetMeanPrice": 13.6, "targetMedianPrice": 14.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 256548992, "totalCashPerShare": 2.558, "ebitda": -170972992, "totalDebt": 85093000, "quickRatio": 7.508, "currentRatio": 8.0, "totalRevenue": 6853000, "debtToEquity": 36.019, "revenuePerShare": 0.071, "returnOnAssets": -0.26612, "returnOnEquity": -0.52789, "freeCashflow": -97108128, "operatingCashflow": -160342000, "grossMargins": 1.0, "operatingMargins": -5.13323, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-16"}]